Lawsuits Against Zantac Spur Department of Justice Investigations
In late July, Reuters and other sources reported that the Department of Justice (DoJ) has opened an investigation into manufacturers of over-the counter ranitidine tablets, including the makers of Zantac. The investigation seeks to determine whether the drug companies Sanofi-Aventis and GlaxoSmithKline (GSK) knew about the potential contamination in ranitidine tablets yet failed to disclose this information. Depending on the findings, pharmaceutical companies and other ranitidine manufacturers may have violated the federal False Claims Act.
Details on the Department of Justice Investigation
The DoJ investigations follow a recent lawsuit filed by the New Mexico Attorney General against several ranitidine manufacturers, including Sanofi-Aventis and GSK, for false advertising and unfair practice violations. In their investigation, the DoJ may determine when Sanofi-Aventis and GSK became aware of the potential contamination of N-nitrosodimethylamine (NDMA) in Zantac. NDMA is classified as a probable human carcinogen by several government organizations, including the
Food and Drug Administration (FDA) and Environmental Protection Agency (EPA).
Background of NDMA in Zantac
The potential dangers of Zantac were uncovered in late 2019 when independent laboratory testing found potentially unsafe levels of NDMA in ranitidine tablets. The online pharmacy Valisure found that NDMA may contaminate ranitidine when the drug was stored above room temperature. This in part led to the FDA requesting that Zantac manufacturers remove all prescription and over the counter ranitidine products in early April. Since the original discovery of NDMA in ranitidine tablets,
hundreds of lawsuits have been filed against the makers of Zantac alleging that long term use of the drug contributed to the development of cancer.
If you or a loved one developed cancer following long-term Zantac or a ranitidine use, you may be entitled to compensation. Navigating your rights following a cancer diagnosis may add additional stress to an already emotionally taxing time. A lawyer from
O’Connor, Acciani & Levy experienced in handling
dangerous drug cases could evaluate the specifics of your claim and help you navigate the best path forward. To speak to one of our knowledgeable Zantac lawyers, contact us today.